

MiMedx®: Giving Physicians Products and Tissues to Help the Body Heal Itself

By Marlene De Simone, SVP, Marketing

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. *"Innovations in Regenerative Biomaterials"* is the framework behind our



The grafts can be utilized right out of the package without a complicated thawing process.


mission to give physicians products and tissues to help the body heal itself. Our six biomaterial product families include: the dehydrated Human Amnion/ Chorion Membrane (dHACM) allograft family with AmnioFix® and Epi-Fix® brands, the Amniotic Fluid family with OrthoFlo brand, Umbilical family with EpiCord® and AmnioCord™ brands, the Placental Collagen family with Colla-Fix™ and AmnioFill™ brands, the Bone family with Physio® brand, and the Skin family with AlloBurn™ brand. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas.

Elected in advance of delivery through our donor program, a mother delivering a healthy baby via scheduled full-term Cesarean section birth may donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 600,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

The Company's proprietary PURION Process is the foundation of the MiMedx AmnioFix and EpiFix products that serve to enhance healing. These products preserve and contain multiple human extracellular matrix components, essential growth factors, and specialized mediating cytokines to modulate inflammation, reduce scar tissue formation, and enhance healing. The healing properties of the membrane have been characterized by comprehensive scientific investigations into the underlying biochemistry and cell biology of how this membrane assists in natural healing

processes. The PURION Process preserves human amniotic membrane tissue, resulting in minimally manipulated tissue products that address numerous serious unmet medical needs requiring healing inside and outside the body. Through the Company's unique process for dehydrating human amniotic tissues, improved clinical outcomes, increased patient quality of life, and reduced financial burden to the healthcare system are achieved.

The MiMedx allografts produced from the Company's proprietary PURION Process for amniotic membrane tissue can be stored at ambient conditions for five years without the need for refrigeration or freezing. The grafts can be utilized right out of the package without a complicated thawing process. These critical qualities of the MiMedx allografts allow hospitals, clinics, and surgeons to immediately provide the appropriate treatment while effectively manage their inventory of allografts. In addition, the grafts are available in multiple sizes and configurations, allowing for size-appropriate grafts for many different wound types.



MiMedx has successfully secured coverage from all of the Medicare Administrative Contractors, Anthem BCBS, HCSC, Cigna, Highmark, HealthNet, TriCare, and 32 State Medicaid plans, most BCBS plans, translating to coverage and reimbursement from over 700 payers.

Results from clinical studies have helped attain coverage, and these published studies include three Randomized Control Trials (RCTs) and a Crossover study. With the publication of multiple randomized, multicenter controlled trials and the support of observational and case studies, the clinical effective-

We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant.

ness of dHACM has been firmly established. The highly statistically significant data from these studies along with multiple published scientific studies have confirmed that the well-known healing properties of this material persist in the multilayer, PURION Processed MiMedx allografts. Clinical, scientific, and economic evidence clearly supports the advantages these products offer physicians, patients and payers. *More information can be found at www.mimedx.com or [click here](#).*